Bristol-Myers Squibb international biopharmaceutical company
Bristol-Myers Squibb is international biopharmaceutical company which was based in 1887 in the USA, New-York.
This is one of the developing pharmaceutical companies in the field of the research activity. In 2011, Bristol-Myers Squibb invested about 4 bln dollars into the research and development of the innovative drugs to treat diseases in such fields of medicine as pancreatic diabetes, cancer, virology, neurology, immunology, and cardiovascular diseases.
In 2009, Bristol-Myers Squibb had a big restructuring results of which became a purchase of 7 new pharmaceutical companies for diversifying production.
As of the end of 2014, Bristol-Myers Squibb takes 15 position among all pharmaceutical company by the sales results. The past 5 years became the most productive and successful for the company.
Now, more than 10 medical products are at the stage of the development and medical research. In order to improve the quality of the drugs and accelerate the developments, Bristol-Myers Squibb follows a strategy of the innovative alliances. Often, the company collaborates with leading pharmaceutical corporations during the creation of new drugs (Pfizer, Sanofi, AstraZeneca).
Bristol-Myers Squibb offers a wide range of medical products for the treatment of:
- Cardiovascular diseases: Avalide, Coumadin, Plavix, Pravachol, Avapro, Eliquis
- Pancreatic diabetes: Farxiga, Glucophage, Glucovance, Komboglyze,
- Infectious and viral diseases: Azactam, Sustiva, Zerit, Megace, Daklinza, Kenalog-40
- Oncologic diseases: Droxia, Erbitux, Lysodren, Opdivo, Taxol, Yervoy
- Mental disorders: Abilify
Bristol-Myers Squibb plans to expand the assortment in years to come, and due to the innovative development of the scientists it will be drugs which will improve people’s lives.